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Abstract
Background: This RCT with two parallel arms will evaluate the efficacy of an internet-delivered transdiagnostic
cognitive behavioural therapy (iCBT) intervention for the treatment of clinical depression and/or anxiety in early
stage cancer survivors.
Methods/design: Early stage cancer survivors will be recruited via the research arm of a not-for-profit clinical research
unit and randomised to an intervention (iCBT) group or a ‘treatment as usual’ (TAU) control group. The minimum
sample size for each group is 45 people (assuming effect size > 0.6, power of 80%, and alpha at .05), but 10%
more will be recruited to account for attrition. A solitary or cumulative diagnosis(es) of Major Depressive Episode
(current), Generalised Anxiety Disorder, Illness Anxiety Disorder, Panic Disorder, Agoraphobia, and/or Adjustment
disorder will be determined using modules from the Anxiety Disorders Interview Schedule for DSM-5. Depression
and anxiety levels with be measured via the total score of the Hospital Anxiety and Depression scale (HADS-
T), the primary outcome measure. Secondary measures will include the Kessler 10 to measure general distress,
the Fear of Cancer Recurrence Inventory (FCRI) to measure the specific fear of cancer recurrence and the
Functional Assessment of Cancer Therapy, General Version 4 (FACT-G) for self-report of physical, social,
emotional and functional well-being. iCBT participants will complete the measures before lessons 1 and 5, at
post-treatment and at 3-month follow-up. The TAU group will complete similar measures at weeks 1, 8 and
16 of the waiting period. Program efficacy will be determined using intent-to-treat mixed models.
Maintenance of gains will be assessed at 3-month follow-up. Mediation analyses using PROCESS will be used to
examine the association between change in depressive and anxious symptoms over time and changes in FCRI and
FACT-G QOL in separate analysis.
Discussion: This is the first RCT looking at iCBT specifically for clinical depression and/or anxiety in a cancer population.
Findings will help to direct the role of iCBT in streamlined psycho-social care pathways.
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Background
Emotional health problems are significantly higher in
cancer survivors (defined as per the National Cancer In-
stitute (NCI) definition, from the time of cancer diagno-
sis to the end of life) than in the general population. In a
recent study, across the different types of cancer, 19% of
patients had clinical levels of anxiety, and 12.9% having
clinical levels of depression. In addition, other patients
had subclinical levels of anxious (22.6%) and depressive
(16.5%) symptoms [1]. Many cancer survivors suffer
long-term emotional distress with symptoms of anxiety
and depression often persisting for years following com-
pletion of cancer treatment [2]. There is a need for sus-
tainable delivery of effective interventions for depression
and anxiety in routine cancer care.
CBT for the treatment of depression and anxiety
in cancer
Fortunately there are clinically effective interventions
available for the treatment of clinical depression and
anxiety disorders in the cancer setting. A 2012 meta-
analysis [3] concluded that Cognitive Behavioural Ther-
apy (CBT) is an effective treatment for depression in
cancer care while earlier studies found evidence for CBT
in treating anxiety [4]. Additionally CBT in cancer care
represents good value for money [5]. The barriers to
accessing the clinically and cost-effective evidence based
treatment of face-to-face CBT for depression and/or
anxiety in the psycho-social context include: under-
recognition of the problem by the patients, under-
recognition of the need for screening and treatment of
emotional health problems within teams and the lack of
appropriately trained mental health professionals in
many communities to provide evidence based care to
cancer patients [6]. Leykin et al. [7] noted that too few
cancer patients and survivors receive evidence-based
interventions for psychological difficulties and that
“internet interventions have the potential to fill an im-
portant gap in quality cancer care by augmenting lim-
ited available mental health services”. Furthermore,
internet interventions overcome privacy and stigma
concerns, allow access to therapy at a time and place
convenient to the patient, including those living in rural
and remote communities, and are reliable, cost-effective
and reproducible [8–10].
Online CBT for emotional health problems comorbid
with physical illness
Online cognitive-behavioural interventions (iCBT) have
been demonstrated to be effective for mild to severe
anxiety and depression in the general population [11]
and the overall effect-size is comparable to face-to-face
CBT [12]. International interest is increasing in harnessing
internet delivered interventions, such as iCBT, to tackle
emotional health symptoms in patients with comorbid
physical health conditions. Trials are underway to evaluate
iCBT in treating comorbid emotional health symptoms in
Cardiology [13, 14], HIV [15] and Diabetes [16].
There are numerous online programs, including some
iCBT interventions, to assist cancer patients. A 2015 litera-
ture analysis identified five social support groups, seven on-
line systems integrating information and four online
therapies for psycho-social/physical symptoms [17]. Some
programs are beginning to show results. In early stage
cancer care, the ‘Finding My Way’ trial [18] provided pre-
liminary support for the efficacy of an online intervention
that teaches participants skills to adjust and cope after
cancer diagnosis. Two further recent small studies have fo-
cused on the emotional health of cancer survivors. A recent
Dutch RCT evaluated the ‘Cancer Aftercare Guide’, a self-
management e-Health intervention [19, 20] which showed
clinically relevant decreases of depression and fatigue in
cancer survivors. An Australian feasibility study specifically
for testicular cancer (eTC) survivors showed preliminary re-
sults in lowering depressive symptoms in a small group of
survivors [21]. There are now larger trials underway looking
at iCBT for severe fatigue in breast cancer survivors [22].
However, no intervention has been evaluated in a rando-
mised controlled trial for a clinical depressive and/or anxiety
disorder. A pilot program looking an CBT principles in a
cancer survivor population with varying depressive symp-
toms [23] “suggests that properly designed web-based inter-
ventions may be effective for reducing depressive symptoms
among cancer patients” and a Canadian feasibility open trial
using a transdiagnostic iCBT intervention, in a group of 18
participants, showed the potential of using iCBT to decrease
depressive and anxious symptoms in cancer survivors [24].
ADAPT and development of iCanADAPT
The development of iCBT tailored to the cancer context
and its integration into clinical care pathways is desirable
Murphy et al. BMC Cancer  (2017) 17:193 Page 2 of 10
at a system wide level to allow the integration of phys-
ical and emotional treatment. Clinical pathways provide
evidence-based recommendations to guide best practice
and consistent care for specific patient concerns in
homogeneous patient groups. Clinical pathways are de-
sirable at a system wide level to allow increased access
to an appropriate level of interventions according to
the severity of the patients’ symptoms [25]. ‘ADAPT’, or
the ‘Anxiety and depression pathway program’, is a
large multi-centred clustered implementation RCT
funded by Cancer Institute NSW in 2015. ADAPT will
evaluate different strategies of integrating and/or im-
proving psycho-social care pathways in cancer care.
One of the strategies included in the ADAPT program
is the potential future use of iCBT as a treatment inter-
vention. The ‘iCanADAPT Early’ iCBT program was
developed as part of ADAPT to specifically address the
needs of early stage cancer survivors, with a co-morbid
clinical depressive and/or anxiety disorder.
The Clinical Research Unit for Anxiety and Depression
(CRUfAD), UNSW at St Vincent’s Hospital, Sydney, has
developed a number of iCBT programs for anxiety and
depressive disorders including a transdiagnostic mixed
anxiety and depressive disorder program for the general
population [26]. CRUfAD modified this proven interven-
tion and further specific cancer content was included.
The further content was influenced by current evidence-
based cancer-specific face to face CBT and a number of
recently developed interventions in heterogeneous can-
cer patients (Finding my way [27], eTC [21]), Conquer
Fear [28]). ‘iCanADAPT Early’ was iteratively reviewed
by an expert panel comprising psycho-oncologists, psy-
chiatrists, and consumers and revised accordingly. The
final iCBT program is clinician supervised and delivered
over a sixteen- week time period. The course is broken
into eight lessons and tailored to the cancer context.
The CBT skills incorporated facilitate the processing of
cognitive and affective aspects of the cancer experiences
and include stress management, problem solving, and
other practical skills to manage symptoms.
Funded by the NSW Institute of Psychiatry, CRUfAD
will conduct an RCT of the ‘iCanADAPT Early’ pro-
gram, comparing the iCBT intervention to treatment as
usual for early stage cancer survivors who meet criteria
for a comorbid diagnosis of anxiety and/ or depression.
Aims of ‘iCanADAPT Early’ study
a) To examine the efficacy of a clinician-guided iCBT
intervention in early stage cancer survivors experi-
encing anxiety and/or depression symptoms.
b) To determine any concurrent changes in general
distress, fear of cancer recurrence, and/or physical,
social, emotional and functional status.
c) To capture the feasibility of this iCBT treatment in
terms of acceptability to patients.
Hypotheses
The hypotheses are that, in a patient population charac-
terised by comorbid early stage cancer survivorship
AND a clinical depression and/or anxiety disorder:
1) iCBT plus treatment as usual will produce clinically
relevant decreases in depressive and anxious
symptoms as shown by a decrease in the total
Hospital and Anxiety Depression Scale (HADS-T)
score (primary outcome measure) compared to a
control group receiving treatment as usual.
2) iCBT plus treatment as usual will produce clinically
relevant decreases in general distress (Kessler 10),
fear of cancer recurrence (Fear of Cancer
Recurrence Inventory (FCRI)) and physical, social,
emotional and functional status (as measured by the
Functional Assessment of Cancer Therapy-General
Version scale (FACT-G QOL)).
3) iCBT plus treatment as usual will be perceived by
patients to be credible (Credibility/Expectancy
Questionnaire(CEQ)), and to be likely to produce
positive impacts.
The RCT was approved by the St. Vincent’s Hospital




This is a parallel group, randomised controlled trial
comparing ‘Treatment as usual’ (TAU) plus up to 8 les-
sons of internet delivered CBT with clinician guidance’
(iCBT) against ‘Treatment as usual’ (TAU).
Study setting
CRUfAD (Clinical Research Unit for Anxiety and Depres-
sion) is a non-profit joint initiative of St. Vincent’s
Hospital, Sydney and the University of New South Wales,
School of Psychiatry in Australia. CRUfAD specialises in
the development, evaluation, and dissemination of
evidence-based CBT programs via the internet. This RCT
will be conducted within the Virtual Clinic, CRUfAD’s
clinical research arm (www.virtualclinic.org.au). The mode
of internet recruitment and delivery enables potential par-
ticipants from all Australian states to apply for enrolment
in the current trial.
Recruitment
Participants will be recruited through flyers, internet so-
cial media advertising, cancer support groups and cancer
research email listings. Applicants will first complete
Murphy et al. BMC Cancer  (2017) 17:193 Page 3 of 10
online screening questionaries about depressive and
anxious symptoms and their demographic details will
be collected. Inclusion criteria to proceed to the phone
interview are as follows; resident of Australia; ≥ 18 years
of age, a total score of ≥ 6 on the Hospital Anxiety and
Depression scale (HADS-T) and a self-report of early
stage cancer or cancer survivorship. This HADS-T
cut-off was chosen as it will allow identification of
95% of cases [29, 30]. Applicants will also be asked a
number of questions related to the exclusion criteria
(see below) and will not proceed to phone interview
if they endorse them. Applicants also complete the
Alcohol Use Disorders Identification Test Consump-
tion (AUDIT-C) questions but are not excluded on
the basis of the results at this stage [31, 32]. See Fig. 1
for a participant flow chart.
Inclusion/exclusion criteria for participation in the trial
All telephone interviews will be conducted by appropri-
ately trained clinical staff. A psychiatry doctor will
undertake the interview if one or more of the follow-
ing are present: elevated HADS-T; any concerns of risk
(elevated passive death wish/suicidality scores); high
scores on AUDIT-C).
The inclusion criteria will be confirmed during the
interview, namely: early stage cancer survivorship; access
to a computer with internet and printer access; Australian
residency; fluency in written and spoken English; will-
ingness to provide name, phone number and address;
and provision of name and contact details of their local
general practitioner. The person will also be invited to
identify their treating cancer centre. Upon confirmation
of the above, the clinician will undertake the relevant
Fig. 1 Participant Flow Chart
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modules from the Anxiety Disorders Interview Sched-
ule for DSM-5. [33] for Major Depressive Episode
(current) (MDD), Generalised Anxiety Disorder (GAD),
Illness Anxiety Disorder (IAD), Panic Disorder (PD),
Agoraphobia (Ag), and/or Adjustment disorder (Adj).
The SCID Adjustment module will only be undertaken
if the applicant has not met criteria for any of the pre-
ceding disorders.
Cancer related exclusion criteria will include any re-
ported metastases, currently being an in-patient, being
within the first 6 weeks of their cancer diagnosis, having
a primary brain cancer (due to potential cognitive
changes), a poor physical health status with an exclusion
of an ECOG (Eastern Cooperative Oncology Group) per-
formance status of greater than 2.
Mental health exclusion criteria will include currently
receiving (i)CBT, or undertaking iCBT in the last year, a
current or past history of schizophrenia or bipolar dis-
order, currently taking antipsychotic medications, fre-
quent suicidality (indicated by a score of ≥ 2 to item 9
Beck Depression Inventory-II (BDI-II), or any concerns
of active addiction on telephone interview.
At the time of telephone interview, any excluded ap-
plicants will receive information on alternative services
and will be encouraged to discuss their symptoms with
their physician.
Applicants who satisfy all inclusion criteria will
complete an electronic informed consent prior to enrol-
ling in the trial. Information from the diagnostic inter-
view will be used for research purposes only for those
participants who provide informed consent. All partici-
pants will be informed in writing that they may with-
draw from the study (i.e. choose to cease program
enrolment or choose for their data to be excluded from
the RCT) at any time without jeopardising their relation-
ship with St. Vincent’s Hospital or the University of New
South Wales. Further, those participants randomised to
the treatment as usual group will be informed that
should they commence a CBT intervention or new psy-
chotropic medication outside of the trial, their data will
be omitted from the RCT.
Trial design and blinding
The trial is a stratified randomised controlled superiority
trial with parallel arms using a 1:1 allocation ratio. It is
stratified according to ‘active treatment’ and ‘post treat-
ment’. The ‘active treatment’ group are those who are at
least six weeks from their initial cancer diagnosis, and
are currently undertaking major cancer treatments such
as chemotherapy or radiotherapy. The ‘post treatment’
group are those who have completed their primary treat-
ment for cancer [34] with no upper timeframe. Experi-
menters and Participants will be aware of their group
allocation but as all measures are self-report blinded
assessors will not be required.
Randomisation
Accepted participants will be stratified according to their
phase in their cancer experience into the ‘active treat-
ment’ group and ‘post-treatment’ group as described
earlier. Thereafter, they will be randomised based on an
allocation sequence generated by an independent person
not involved in the study via a true randomisation process
(www.random.org). Numbers corresponding to treatment
group (1 = iCBT) or the treatment as usual group (2 =
TAU) will be placed in sealed opaque envelopes bearing
the sequential order number to ensure participant allo-
cation based on the pre-determined randomisation se-
quence. A member of the research team will open the
envelope after the diagnostic interview.
Trial procedure
Figure 1: Participant Flow Chart details the time line for
participants in the study. Once randomised, participants
will be allocated to either the iCBT arm or the TAU arm.
Over the sixteen week period, both groups undertake
the same set of measures three times, the start, mid-
point and end of the intervention. In the iCBT group,
these times will vary according to when the participant
undertakes the specific lesson; whereas for the TAU
group, the questionnaires are according to specific times
(i.e. weeks since commencement of group). Administra-
tion time points for measures are contained in Table 1.
Baseline records of psychotropic medications and
whether they are accessing psychological support will be
captured for participants in both groups. Participants
will be asked to inform the research team if any of their
current interventions change.
Description of the interventions
Internet delivered CBT (iCBT), the ‘iCanADAPT Early’
program group
The ‘iCanADAPT Early’ Program is a self-managed,
16 week online cognitive-behavioural intervention con-
sisting of eight lessons involving general CBT skills and
then cancer-specific CBT skills. Content is presented in
the form of an illustrated comic-based storyboard in
which two animated characters gain mastery over their
anxiety and depressive symptoms with the help of a clin-
ician. The female character is currently undergoing can-
cer treatment and tackling clinical levels of depression,
while the male character is post-treatment with predom-
inant anxiety symptoms. The participant follows both
characters journeys to recovery across the 8 lessons. The
title, and expansion of the main focus of each lesson are
in Table 2: Course overview.
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At the end of each lesson, participants download a
Lesson Summary which expands on the cartoon story-
board and provides a structured outline of the information.
It also encourages participants to complete homework ac-
tivities and review the lesson content at a later date. Extra
resources are provided to participants and include work-
sheets examples.
Clinician guidance for iCBT group
Each participant’s scores and engagement are monitored
over the course of the working week. At minimum, indi-
vidual email contact is made to each participant after
the completion of Lesson 1 and Lesson 2. Thereafter,
further email and/or phone contact will be made to par-
ticipants depending on their needs. Typical reasons for
clinician contact include an increase in distress scores, a
participant question relating to content or a participant
taking an unexplained break from logging in. Partici-
pants will have the opportunity to volunteer feedback
about their most recent lesson/week(s) before each sub-
sequent lesson and these responses will occasionally
prompt clinician contact.
Treatment as usual (TAU) group
Participants allocated to the TAU group may access their
local general practitioner, community or cancer centre
(mental) health services during the course of their wait-
ing period.
Clinician guidance for TAU group
Each participant’s questionnaire responses (week 1, 8
and 16) are reviewed. A generic email is sent from the
Virtual Clinic system to thank participants for complet-
ing their questionnaire. Clinician contact will only be
made if there are unexpected high HADS, or K-10
scores, or significant change from the scores previously
obtained. Upon completion of the 16-week waiting
period, and upon completion of the final set of TAU
questions, the participants will transition to iCBT and
then receive clinician guidance during their iCBT pro-
gram as described above.
Measures
Primary outcome measure
Hospital anxiety and depression scale, total score
(HADS-T)
The primary endpoint is anxiety and depression severity at
post treatment as measured by the Hospital Anxiety and
Depression Scale Total score (HADS-T) [35]. The HADS
was developed as an outcome measure to assess anxiety
and depression that avoids reliance on the measurement of
somatic symptoms (e.g., fatigue, or insomnia) that may be
experienced by people with cancer as part of the presenting
illness. HADS-T is a fourteen item self-report questionnaire
divided into two sub-scales, HADS-D, depression subscale
and HADS-A, an anxiety subscale. The HADS-T is the
total HADS score and is the combined score of the depres-
sive and anxiety sub-scales. High scores indicate greater
morbidity. This validated measure is widely used in clinical
settings and has been validated in cancer patients [29].
Secondary outcome measures
Kessler-10 Psychological Distress Scale (K10) [36]:
The K10 contains 10 items ranked on a 5-point scale de-
signed to measure non-specific psychological distress.
High scores indicate higher distress. The K10 has been
validated in a mixed cancer-type population [37]. Fur-
thermore, the K10 is a quickly administered online tool
Table 1 Administration time points for questionnaires used in the RCT
Measure Pre-treatmenta Before each
lessonb
Mid –treatmentc Post-treatmentd 3-month
follow-upb
HADS-T ♦ ♦ ♦ ♦
K-10 ♦ ♦ ♦ ♦ ♦
PHQ9-Q9 ♦ ♦ ♦ ♦
BDI-II Item 9 ♦ ♦ ♦ ♦
FCRI ♦ ♦ ♦ ♦
FACT-G ♦ ♦ ♦ ♦
CEQ ♦ ♦
ADIS ♦ ♦
HADS-T Hospital Anxiety and Depression Scale,Total score, K-10 Kessler-10 Psychological Distress Scale, PHQ9-Q9 Patient Health Questionnaire 9-itme scale, Question 9,
BDI-II Item 9 Beck Depression Inventory-II, Item 9, FCRI Fear of Cancer Recurrence Inventory, FACT-G Functional Assessment of Cancer Therapy – General, CEQ Credibility
and Expectancy/Satisfaction Questionnaire, ADIS Anxiety Disorders Interview Schedule for DSM-5
aiCBT group pre Lesson 1; TAU group at week 1 (Baseline)
biCBT group only
ciCBT group pre Lesson 5; TAU group at week 8
d iCBT group post Lesson 8; TAU group at week 16 (End)
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and is advantageous for monitoring iCBT patients [38].
For the current study, the time frame was modified to
assess psychological distress in the past 2 weeks rather
than the past 30 days.
Patient Health Questionnaire 9-item scale, Question
9 (PHQ9-Q9 [39]) and Beck Depression Inventory-II,
Item 9 (BDI-II,i9), [40]: The HADS-T and the K-10 do
not contain questions regarding either a passive death
wish or suicidal ideation. Therefore, these two screening
questions for ‘better off dead’ thoughts and suicidality are
included in the assessment of patients, and score changes
are automatically reported. These questions allow the
monitoring clinician to make contact with participants
should changes occur.
Fear of Cancer Recurrence Inventory (FCRI) [41]:
The 42-item Fear of Cancer Recurrence Inventory was
chosen as it is an aggregate score of seven sub-scales
ranging from triggers to level of insight into the prob-
lem. The FCRI severity subscale is reported to be the
most informative regarding a patient’s level of fear [42].
High scores indicate greater fear of cancer recurrence.
Possible associations between the FCRI subscale scores
and the clinical diagnoses via the ADIS, and/or other
determinants [43] including treatment response, will
be assessed.
Functional Assessment of Cancer Therapy – General
(FACT-G, version 4) [44]: The FACT-G is a 33-item gen-
eral cancer quality-of-life measure. FACT-G has been
established as a valid and reliable measure [45]. FACT-G
was chosen over other quality of life measures as it has
scales looking at the impact of symptoms on relationships
and supports [46].
Credibility and Expectancy/Satisfaction Questionnaire
(CEQ) [47]: At baseline, participants will complete two
treatment expectancy questions: (1) “At this point, how lo-
gical does the program offered to you seem?” (0 = “Not at
all logical”; 9 = “Very logical”) and (2) “At this point, how
successfully do you think this treatment will be in reducing
your depression and anxiety symptoms?” (0 = “Not at all
useful”; 4 = “Very useful”). Following the combined inter-
vention, participants will also rate treatment satisfaction:
“How satisfied are you with the skills that this program
has taught you to manage your depression and anx-
iety?” (1 = “Not at all satisfied”; 9 = “Very satisfied”);
“How confident would you be in recommending this
treatment to a friend who experiences similar problems?”
(1 = “Not at all confident”; 9 = “Very confident”); followed
by two questions about difficulty with the program
and requesting additional feedback, which will require
free text responses.
Data management
All data will be collected via the Virtual Clinic software
and stored on the Virtual Clinic server. All information
collected will be coded with a participant identification
number to allow data-to-patient matching. Additional
clinical material not obtained via the online application,
mainly pertaining to data obtained via the diagnostic in-
take interview, will be collected and stored in written
format in a secure location in CRUfAD. Any identifiable
information will remain confidential, except as required
by law. Only members of the site research team will have
access to participant information and data in order to
monitor patient progress. During data analysis, re-
identifiable data (i.e. coded data) will be used. At study
completion, non-identifiable data will be written to a
password-protected database. All data will be extracted
from the Virtual Clinic servers. Analysis will be con-
ducted using Statistical Package for the Social Sciences
(IBM SPSS, IBM Corp., Armonk, NY, USA).
Participants will be informed in writing that the re-
search team plans to disseminate the trial results in
peer-reviewed scientific publications and presentations.
Participants are informed that in any such dissemin-
ation, their anonymity will be maintained. Participants
will be sent (via email) a written summary of the results
in lay terms following completion of the trial study
phase.
Table 2 Course overview
Lesson 1 - Learning about Depression & Anxiety
Psycho-education about depression and anxiety, including their
prevalence in cancer, psycho-education about the CBT cycle and the
flight or fight response. Introduction to rumination and worry and
good sleep hygiene. Skills of relaxation and progressive muscle
relaxation.
Lesson 2 - Identifying and Tackling Thoughts
Key cognitive therapy skills including cognitive monitoring,
recognising distorted cognitive styles, and later cognitive
restructuring. Examples of each skill in use.
Lesson 3 - Tackling Unhelpful Behaviours
Key behavioural activation skills including tackling the low activity
cycle, daily activity scheduling and the role of physical activity in
improving general health. Additional skills relating to structured
problem solving and assertive communication skills.
Lesson 4 - Helpful Coping
Further cognitive skills including worry-Free Zones and challenging
mega-cognitions. Expanded attention to CBT strategies to tackle sleep
difficulties. An introduction to mindfulness and related extra resources.
Lesson 5 - Adjusting to Change
Assessment of one’s personal values and goals. The need to pace
physical activity. The use of CBT to tackle the impact of physical
health (and/or treatment) symptoms on emotional wellbeing.
Lesson 6 - Tackling Avoidance
Introduction to avoidance and the rationale for combatting
avoidance using graded exposure and exposure stepladders.
Numerous examples of confronting avoidance (both in cancer and
non-cancer settings) are intertwined to allow generalisation.
Lesson 7 - Mastering Your Skills
A guide to potential pitfalls that people encounter when trying to
master CBT skills, in particular that of exposure work. An introduction to
imaginal exposure.
Lesson 8 - Staying Well in the Long Term and Getting Even Better
Relapse prevention planning and an overview of the skills learned.
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Statistical methods
There is no prior published research outlining effective-
ness of iCBT for treatment of a clinical depression or
anxiety disorder in a cancer setting. In order to calculate
sample size, data was taken from published randomised
controlled trial of a transdiagnostic iCBT program [26].
Assuming the effect size of >0.6, and taking power at
80% with alpha set at 0.05%, sample size is calculated to
be 44 per group. This is to detect a 0.6 effect size for the
iCBT group to improve more than the treatment as
usual group. Recruitment of 50 per group will be under-
taken to account for attrition.
All analyses will be conducted at conclusion of the trial
period, i.e. when all participants in the treatment group
have completed the iCBT program. All analyses will be
implemented in SPSS. Consideration will be given to the
stratification into ‘active treatment’ and ‘post-treatment’.
Significance testing of group differences regarding
demographic data and pre-treatment measurements will
be conducted using analysis of variance (ANOVA) and
χ2 where the variables consist of nominal (or categorical)
data. Intent-to-treat (ITT) mixed models using restricted
maximum likelihood (REML) estimation will be used to
account for missing data due to participant drop-out.
Mixed models do not assume that the last measurement
is stable (the last observation carried forward assump-
tion) [48, 49]. REML models are appropriate for RCTs
with multiple time points and pre-to post-only designs
[50]. The assumption that data are missing at random
(MAR) will be evaluated using binary logistic regression
to predict drop-out (0 = no drop-out, 1 = drop-out) and
by comparing these two groups on baseline measures.
Significant effects will be followed up with pairwise con-
trasts comparing mean pre-treatment to mean post-
treatment scores. Mediation analyses will be used to
examine the association between change in depression
and anxiety symptoms over treatment and change in
each of FCRI and FACT-G in separate analyses. Tests of
the indirect effects (mediation) will be conducted using
PROCESS [51].
Discussion
This RCT will evaluate the efficacy of an iCBT interven-
tion for clinical depression and/or anxiety in people with
early stage cancer going through treatment or post-
treatment. As the majority of e-health interventions in
psycho-oncology to date focus on supportive care [17],
this is a novel program as it will evaluate iCBT in clinical
depression and/or anxiety. Fortunately, cancer survivors
have an overall “positive attitude” to self-management
and e-Health [52].
If proven efficacious, and acceptable to patients, the
iCBT intervention would be added to the armoury of
psychological treatments offered to cancer survivors
suffering from anxiety and depression symptoms gener-
ally. It will be a core component of the forthcoming
ADAPT Cluster Randomized Controlled trial. Moorey
[53] importantly asked in 2013 “I know they are dis-
tressed, what do I do now?”., He outlines that, despite
many advances in Psycho-Oncology, services need to in-
corporate less labour intensive methods of delivery of
therapy (primarily CBT), in order to be widely accessible
and sustainable. He proposed that internet therapy will
have a role in the changing interface of how care is pro-
vided in the cancer setting. This trial will add to the re-
search aiming to address the short fall he outlines. It will
add to recent work on the role of online interventions in
other areas of supportive care, such as fatigue and acute
distress [54], for people living with, or survivors of can-
cer. As an RCT aiming to recruit over 100 participants,
it will add to the literature base and build on the pilot
and feasibility studies in this area of psycho-oncology.
Furthermore this trial will add to the growing literature
of the use of iCBT for treating emotional health prob-
lems in patients with a co-morbid physical illness.
Online, or internet, interventions are easy to access,
including in rural areas, accessible by the user at any
time, private and confidential, self-empowering, scalable
and cost-effective and can meet the needs of most pa-
tients, freeing staff to see only the most severe cases
[11]. As Mitchell [55] pointed out “screening is generally
ineffective without aftercare”; hopefully iCBT can become
a viable, evidence-based treatment option in the future,
thereby increasing treatment afforded to patients screen-
ing positive for distress and depression.
Trial status
Trial registration: Australian New Zealand Clinical
Trials Registry: ACTRN12616000231448, registered 19th
February 2016 (www.anzctr.org.au). This trial protocol is
in compliance with the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guidelines.
The first patient was enrolled 01st March 2016. Data ana-
lysis is scheduled for late 2017.
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